Takeda Pharmaceutical (NYSE:TAK) Insider Lauren Rusckowski Duprey Sells 34,535 Shares

Takeda Pharmaceutical Co. (NYSE:TAK) insider Lauren Duprey sold 34,535 shares of the stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $18.54, for a total transaction of $640,278.90. Following the sale, the insider directly owned 191,522 shares in the company, valued at $3,550,817.88. This trade represents a 15.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Lauren Rusckowski Duprey also recently made the following trade(s):

• On Monday, August 10th, Lauren Duprey sold 47,586 shares of Takeda Pharmaceutical stock. The stock was sold at an average price of $17.10, for a total transaction of $813,720.60.

Takeda Pharmaceutical Stock Up 0.6%

NYSE:TAK opened at $18.71 on Wednesday. The stock’s fifty day moving average price is $17.58 and its two-hundred day moving average price is $17.19. Takeda Pharmaceutical Co. has a 52-week low of $12.99 and a 52-week high of $18.90. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.62 and a current ratio of 1.14. The company has a market cap of $59.95 billion, a price-to-earnings ratio of 55.03 and a beta of -0.07.

Takeda Pharmaceutical (NYSE:TAK) last released its earnings results on Thursday, July 30th. The company reported $0.95 EPS for the quarter, beating the consensus estimate of $0.41 by $0.54. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%.The company had revenue of $7.50 billion during the quarter, compared to analysts’ expectations of $7.13 billion. Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. On average, analysts anticipate that Takeda Pharmaceutical Co. will post 1.54 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Weiss Ratings upgraded shares of Takeda Pharmaceutical from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday. Wall Street Zen upgraded shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Finally, Zacks Research raised shares of Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, September 2nd. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy”.

Hedge Funds Weigh In On Takeda Pharmaceutical

Several institutional investors have recently modified their holdings of TAK. Capital Research Global Investors boosted its stake in Takeda Pharmaceutical by 0.6% during the 4th quarter. Capital Research Global Investors now owns 13,486,772 shares of the company’s stock worth $210,259,000 after acquiring an additional 82,643 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its stake in Takeda Pharmaceutical by 100.9% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 5,682,847 shares of the company’s stock valued at $88,596,000 after purchasing an additional 2,854,069 shares in the last quarter. Renaissance Technologies LLC raised its holdings in Takeda Pharmaceutical by 14.2% in the first quarter. Renaissance Technologies LLC now owns 2,989,100 shares of the company’s stock worth $55,358,000 after purchasing an additional 370,800 shares during the period. Quantinno Capital Management LP raised its holdings in Takeda Pharmaceutical by 20.6% in the first quarter. Quantinno Capital Management LP now owns 1,289,326 shares of the company’s stock worth $23,878,000 after purchasing an additional 219,999 shares during the period. Finally, Royal Bank of Canada boosted its position in shares of Takeda Pharmaceutical by 11.0% during the first quarter. Royal Bank of Canada now owns 614,851 shares of the company’s stock worth $11,386,000 after purchasing an additional 60,725 shares in the last quarter. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited is a global biopharmaceutical company headquartered in Japan. The company researches, develops, manufactures and markets prescription medicines and vaccines for patients and healthcare professionals around the world.

Takeda focuses on several therapeutic areas, including gastrointestinal and inflammatory diseases, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Its portfolio includes treatments such as Entyvio for inflammatory bowel disease, Takhzyro for hereditary angioedema, Ninlaro for multiple myeloma and Iclusig for certain blood cancers, along with other specialty medicines and vaccines.

Founded in Osaka in 1781, Takeda has grown from a traditional pharmaceutical distributor into an international biopharmaceutical company serving markets across Japan, North America, Europe and other regions.